UPMC Hillman Cancer Center | Strategic Alliance Partners

April 19, 2023

Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.

April 19, 2023

Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.

April 12, 2023

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

April 12, 2023

Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.

April 05, 2023

Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.

April 05, 2023

Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.

March 29, 2023

Expert perspectives on real-world, in-practice identification and management of patients with resectable CSCC.

March 29, 2023

Panelists round out their review of staging and risk stratification in CSCC by considering how each affects the selection of optimal surgical strategies.

March 22, 2023

Following their discussions on staging and risk stratification in CSCC, key opinion leaders work to define resectability in cutaneous squamous cell carcinoma.

March 22, 2023

Expert panelists share their perspectives on best strategies to risk stratify patients diagnosed with cutaneous squamous cell carcinoma.

March 21, 2023

Yvonne Chao, MD, PhD, discusses key trials leading to FDA approvals in metastatic non–small cell lung cancer.

March 21, 2023

Timothy Burns, MD, PhD, discusses the evolving use of antibody-drug conjugates in HER2-mutant non–small cell lung cancer.

March 15, 2023

A review of current staging systems used to categorize CSCC, particularly those from the American Joint Committee on Cancer and Brigham and Women's Hospital.

March 15, 2023

Opening their discussion on resectable cutaneous squamous cell carcinoma (CSCC), expert panelists elucidate its current incidence and known risk factors.

March 02, 2023

Anwaar Saeed, MD, discusses biomarkers that signal the potential efficacy of frontline immunotherapy regimens in patients with advanced esophageal squamous cell carcinoma.

February 24, 2023

Yvonne Chao, MD, PhD, discusses the study of various PD-L1 inhibitors in patients with non–small cell lung cancer.

February 02, 2023

Timothy Burns, MD, PhD, discusses the evolution of EGFR-targeted non–small cell lung cancer treatments, the importance of delineating small cell lung cancer subtypes, and the advantages of continued antibody-drug conjugate development across all areas of lung cancer.

November 28, 2022

The combination of the p38 MAPK inhibitor ARRY-614 plus nivolumab with or without ipilimumab was well tolerated and elicited disease control in high-risk, PD-(L)1–refractory patients with advanced solid tumors.

October 13, 2022

A new study pinpoints how LAG3 modulates T cell activity, providing important insights for development of other LAG3-blocking therapies for cancer and autoimmune disorders.

June 05, 2022

Treatment with lisocabtagene maraleucel resulted in a high rate of durable overall and complete responses as second-line therapy in frail patients with relapsed/refractory large B-cell lymphoma for whom hematopoietic stem cell transplantation was not intended, according to preliminary findings from the phase 2 PILOT study.